ELISA/ACT® Biotechnologies LLC introduces LRA Dental and Orthopedic Materials Testing

STERLING, VA – ELISA.ACT Biotechnologies announces the recent launch of LRA Dental and Orthopedic Materials Testing. Unlike traditional allergy testing methods such as skin prick or antibody-based blood tests, the LRA Dental & Orthopedic Materials testing focuses on identifying sensitivities mediated by T cells, which trigger delayed immune responses and can lead to inflammation or other symptoms. These tests are beneficial in identifying specific sensitivities that may contribute to chronic health issues or persistent symptoms.

These LRA panels include 45 chemical antigens that exhibit reactivity with greater frequency and are commonly found in a wide range of dental and orthopedic materials. The tests evaluate positive reactions and correlate this information with a database of more than 25,000 trade-named dental and orthopedic materials. This extensive evaluation allows for the accurate identification of potential reactive chemicals.

ELISA/ACT Biotechnologies’ founder, Dr. Russell Jaffe says, “Knowing which materials your body is reactive to will provide you the knowledge and peace of mind to undergo dental and orthopedic procedures without unnecessary complications and prolonged healing.”

Contact ELISA/ACT Biotechnologies Client Services (800-553-5472) or your Clinical Account Specialist.


About ELISA/ACT Biotechnologies

ELISA/ACT Biotechnologies® (EAB) is the exclusive provider of the lymphocyte response assay (LRA by ELISA/ACT) tests – the gold standard in delayed hypersensitivity testing. Built on a strong foundation of patented technology, patient-friendly guidance, value-added support, and proven results, EAB will provide you with a successful plan to determine and address the causes of chronic disease and immune system dysfunction and restore overall health. For over 30 years, our clinically proven, proprietary tests and individualized treatment plans have been  used successfully in managing chronic autoimmune and immune dysfunction syndromes. ELISA/ACT Biotechnologies is a PERQUE Integrative Health company. Visit ELISAACT.com for more.

About Dr. Russell Jaffe

Dr. Russell M. Jaffe, CEO and Chairman of PERQUE Integrative Health is one of the pioneers of integrative and regenerative medicine. Since inventing the world’s first single step amplified (ELISA) procedure in 1984, a process for measuring and monitoring all delayed allergies, Dr. Jaffe has continually sought new ways to help speed the transition from our current healthcare system’s symptom-reactive model to a more functionally integrated, effective and compassionate system. PIH is the outcome of years of Dr. Jaffe’s scientific research. It brings to market three decades of rethinking safer, more effective, novel and proprietary dietary supplements, supplement delivery systems, diagnostic testing, and validation studies.